Humacyte, Inc. — Director's Dealing 2025

Apr 15, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Humacyte, Inc. (HUMA)
CIK: 0001818382
Period of Report: 2025-04-14

Reporting Person: Scheessele William John (Chief Commercial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-04-14	Common Stock	P	6493	$1.54	Acquired	22018	Direct